Shield Therapeutics (STU:1JS) Other Current Receivables: €1.93 Mil (As of Dec. 2025)


What is Shield Therapeutics Other Current Receivables?

Shield Therapeutics STU:1JS Other Current Receivables is €1.93 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Shield Therapeutics's Other Current Receivables for the quarter that ended in Dec. 2025 was €1.93 Mil.

Shield Therapeutics's quarterly Other Current Receivables declined from Dec. 2024 (€9.79 Mil) to Jun. 2025 (€0.00 Mil) but then increased from Jun. 2025 (€0.00 Mil) to Dec. 2025 (€1.93 Mil).

Shield Therapeutics's annual Other Current Receivables increased from Dec. 2023 (€0.56 Mil) to Dec. 2024 (€9.79 Mil) but then declined from Dec. 2024 (€9.79 Mil) to Dec. 2025 (€1.93 Mil).

Shield Therapeutics Other Current Receivables Related Terms

Shield Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Other Current Receivables Chart

Shield Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.57 0.56 9.79 1.93

Shield Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.00 9.79 0.00 1.93

Shield Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €1.93 Mil mean?
Shield Therapeutics (STU:1JS) has a Other Current Receivables of €1.93 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Shield Therapeutics and its competitors.
Is Shield Therapeutics' Other Current Receivables too high?
Shield Therapeutics' current Other Current Receivables is €1.93 Mil.
How does Shield Therapeutics' Other Current Receivables compare to ZTS and UTHR?
Shield Therapeutics' Other Current Receivables of €1.93 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Shield Therapeutics and its competitors. Shield Therapeutics's current Other Current Receivables is €1.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current Other Current Receivables is €1.93 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Other Current Receivables is €1.93 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges SHIEF:USASTX:UK1JS:Germany
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.